Li L H, Wallace T L, Richard K A, Tracey D E
Cancer Res. 1985 Feb;45(2):532-8.
This study was undertaken in an attempt to understand the mechanism of antitumor action of pyrimidinones alone and in combination with cyclophosphamide (CY). Pyrimidinones such as 2-amino-5-bromo-6-(3-fluorophenyl)-4(3H)pyrimidinone (ABMFPP) were relatively nontoxic toward murine L1210 leukemia cell growth in vitro with the concentration of drug required for a 50% inhibition of cell growth being greater than 50 micrograms/ml. In contrast, ABMFPP showed anti-B16 melanoma activity in vivo which was sensitive to X-irradiation of the hosts. These results collectively suggest that pyrimidinones may act differently from conventional cytotoxic antitumor agents. Multiple i.p. injections of ABMFPP (125 mg/kg/injection) significantly augmented the cytotoxicity of both natural killer cells and macrophages in peritoneal exudates. The augmentation of both effector cell populations was delayed, but was more pronounced when animals received a dose of CY (100 mg/kg) prior to ABMFPP injections. The combination of CY and ABMFPP also showed a synergistic anti-P388 leukemia effect which appeared to be related to the initial reduction of the tumor burden by CY and the marked augmentation of the cytotoxicity of both natural killer cells and macrophages by ABMFPP. The antitumor activity of ABMFPP against B16 melanoma was almost completely eliminated when animals received a dose of 400 rads X-irradiation 5 days prior to tumor inoculation or a dose of 200 rads X-irradiation followed by several injections of anti-asialo monosialoganglioside antibody. The administration of anti-asialo monosialoganglioside alone also markedly reduced the anti-B16 melanoma activity of ABMFPP. The magnitude of reduction of the antitumor effect of ABMFPP by radiation and/or anti-asialo monosialoganglioside antibody directly correlated with the inhibition of the ABMFPP-mediated augmentation of immune responses. These results strongly suggest that the antitumor effect of ABMFPP alone or in combination with CY is at least in part mediated through its augmentation of natural killer cell and/or macrophage activities.
本研究旨在了解嘧啶酮单独使用及与环磷酰胺(CY)联合使用时的抗肿瘤作用机制。嘧啶酮如2-氨基-5-溴-6-(3-氟苯基)-4(3H)嘧啶酮(ABMFPP)对小鼠L1210白血病细胞体外生长的毒性相对较小,抑制细胞生长50%所需的药物浓度大于50微克/毫升。相比之下,ABMFPP在体内表现出抗B16黑色素瘤活性,且对宿主的X射线照射敏感。这些结果共同表明,嘧啶酮的作用方式可能与传统的细胞毒性抗肿瘤药物不同。多次腹腔注射ABMFPP(125毫克/千克/次)可显著增强腹腔渗出液中自然杀伤细胞和巨噬细胞的细胞毒性。两种效应细胞群体的增强作用出现延迟,但当动物在注射ABMFPP之前接受一剂CY(100毫克/千克)时,增强作用更为明显。CY与ABMFPP的联合使用还显示出协同抗P388白血病效应,这似乎与CY最初降低肿瘤负荷以及ABMFPP显著增强自然杀伤细胞和巨噬细胞的细胞毒性有关。当动物在接种肿瘤前5天接受400拉德X射线照射或接受200拉德X射线照射后多次注射抗去唾液酸单唾液酸神经节苷脂抗体时,ABMFPP对B16黑色素瘤的抗肿瘤活性几乎完全消除。单独给予抗去唾液酸单唾液酸神经节苷脂也显著降低了ABMFPP的抗B16黑色素瘤活性。辐射和/或抗去唾液酸单唾液酸神经节苷脂抗体降低ABMFPP抗肿瘤作用的程度与抑制ABMFPP介导的免疫反应增强直接相关。这些结果强烈表明,ABMFPP单独或与CY联合使用的抗肿瘤作用至少部分是通过增强自然杀伤细胞和/或巨噬细胞活性介导的。